Maritech Fucoidan Extracts Get FDA GRAS
Maritech fucoidan ingredients are the first and only high-purity fucoidan extracts to achieve GRAS status, says the company.
Photo © iStockphoto.com/BryanToro
A biotechnology company called Marinova Pty. Ltd. (Tasmania, Australia) announced that its proprietary fucoidan extract is now Generally Recognized as Safe (GRAS) by FDA. Maritech fucoidan ingredients are the first and only high-purity fucoidan extracts to achieve GRAS status, says the company.
The FDA responded “no questions” to findings by an independent panel of experts. The panel determined that the fucoidan extracts from two species of seaweed-Undaria pinnatifida and Fucus vesiculosus-are safe for use as a food ingredient in dosages of up to 250 mg per day. Fucoidan is a bioactive polysaccharide that occurs naturally in brown seaweed, and the company says that its fucoidan extracts have been shown to support immune and digestive health, possess antiaging properties, and may aid in tumor suppression, anti-inflammation, and viral inhibition.
“GRAS recognition is testament to the safety and quality of Maritech fucoidan extracts, giving our customers even further confidence that they are getting the highest quality and most effective fucoidan ingredients on the market,” said Damien Stringer, PhD, operations manager, Marinova, in a press release.
The company notes that this GRAS status achievement follows previous regulatory accreditations in such markets as Australia, Canada, Europe, and China, among others. The extracts have also been granted non-GMO, Kosher, and Halal certifications.
Also read:
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
